EANS-Adhoc: Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act): Epigenomics AG Announces Capital Increase

ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement.

Restructuring & Recapitalisations/Company Information/molecular diagnostics 20.12.2012

Not for distribution in the United States

Berlin, Germany, December 20, 2012 - Today the Executive Board of Epigenomics AG, Berlin, Germany (Frankfurt Prime Standard: ECX; ISIN: DE000A1K0516), with the approval of the Supervisory Board, has taken the decision to implement an increase of the issued share capital by utilization of authorised capital. The capital increase shall be carried out by way of a rights issue against cash contributions. It shall be structured in such a manner that the gross proceeds generated under the capital increase will amount to up to just under EUR5,000,000 in order to make use of the available exemption from the publication of a prospectus under German securities laws.

In early January 2013, the Supervisory and Executive boards of the Company plan to resolve the details of the capital increase, in particular the maximum number of new shares and the subscription ratio, which will then be published by way of an ad hoc announcement without undue delay. Publication of the subscription offer and beginning and end of the subscribtion period will subsequently take place in line with German market practice.

The new shares will first be offered to the shareholders of the Company. Shares not taken up by sharesholders might subsequently be offered in a private placement to institutional investors.

Epigenomics AG intends to use the net proceeds from the offering to finance its current operations and to build and strengthen the distribution capacities for its products.

- End of Ad hoc -

Disclaimer

This publication is not an offer of any securities for sale or a solicitation of an offer to purchase any securities.

This document is not an offer of securities for sale or a solicitation of an offer to purchase securities in the United States. The shares of Epigenomics AG (the "Shares") have not been registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to an exemption from such registration. There will be no public offering of the Shares in the United States and the Shares will not be registered under the Securities Act.

Contact:

Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com

end of announcement euro adhoc

issuer: Epigenomics AG Kleine Präsidentenstraße 1 D-10178 Berlin phone: +49 30 24345-0 FAX: +49 30 24345-555 mail: ir@epigenomics.com WWW: http://www.epigenomics.com sector: Biotechnology ISIN: DE000A1K0516 indexes: Prime All Share, Technology All Share

stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart, regulated dealing/prime standard: Frankfurt
language: English

Digital press kit: http://www.ots.at/pressemappe/EASY_38683/aom

Rückfragen & Kontakt:

Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com

ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | EAE0005